High-grade gliomas are amongst the most aggressive cancers due to their resistance to conventional therapy. Resistance to genotoxic modalities has been attributed to a highly tumorigenic subpopulation of stem-like cells within these tumors. Our previous work has demonstrated that a Central Nervous System-specific transcription factor, OLIG2, is expressed within these `stem-like' cells and is required for glioma formation in orthotopic patient-derived xenografts (PDX) as well as in a genetically defined mouse model of glioma. We have shown that ablation of OLIG2 can suppress tumor growth as well as radiosensitize glioma cells in a p53 dependent manner. Our data suggest that a small molecule inhibitor of OLIG2 could serve as a highly targeted therapy for high grade glioma. However, transcription factors are generally difficult to target. In this study, we propose to target druggale OLIG2 partner proteins (HDAC1 and FYN) as a surrogate means for glioma therapy. In preliminary results, we have identified Histone deacetylase 1(HDAC1) and FYN kinase as novel interactors of OLIG2. We show that knockdown of HDAC1 significantly decreases glioma cell survival, while there is minimal effect on normal neural stem cells. Further, FYN tyrosine kinase interacts with and phosphorylates OLIG2 and its knockdown affects OLIG2 transcriptional functions. We hypothesize that the pro-mitogenic functions of phospho-OLIG2 requires interaction with its partner proteins, HDAC1 and FYN kinase.
In Aim 1, we will test the hypothesis that the pro-mitogenic functions of Olig2 are primarily channeled through HDAC1.
In Aim 2, we will test the hypothesis that the pro-mitogenic functions of OLIG2 in gliomas require interaction with and phosphorylation by Fyn kinase. Lastly, in Aim 3, we will collaborate with Dr. LaBaer's group to test our hypothesis that pOLIG2 interacts with distinct partner proteins under oncogenic conditions. At the conclusion of these experiments we would have identified: a) the molecular mechanism involved in OLIG2-mediated proliferation through HDAC1; b) identified a highly targeted means to inhibit glioma growth, c) shown how the proto-oncogene FYN kinase regulates OLIG2 function and d) mapped novel phospho-Olig2 and glioma specific partner proteins as novel means to target OLIG2 function. In future, these studies will provide the rationale for developing highly targeted (HDAC1/FYN-specific) therapies for glioma.

Public Health Relevance

Malignant gliomas are the most aggressive type of brain tumor with median survival of only 9-14 months after diagnosis. Our studies have shown that targeting Olig2 function can suppress tumor growth and sensitize glioma cells to therapy. Olig2 promotes tumor growth in part by blocking tumor suppressor p53 function. Olig2 is a transcription factor which is typically difficult to drug. The goal of this proposal is to target druggable Olig2 partner proteins (HDAC1 and FYN) that are critical for tumor formation as a surrogate means for glioma therapy. In addition, we will identify tumor-specific co-regulators of Olig2, which might serve as novel drug targets, either stand alone or in conjunction with conventional treatments for high-grade glioma. Successful completion of our studies will pave way for more targeted therapy for this deadly disease.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS088648-01A1
Application #
9030293
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Fountain, Jane W
Project Start
2015-09-30
Project End
2020-07-31
Budget Start
2015-09-30
Budget End
2016-07-31
Support Year
1
Fiscal Year
2015
Total Cost
Indirect Cost
Name
St. Joseph's Hospital and Medical Center
Department
Type
DUNS #
131606022
City
Phoenix
State
AZ
Country
United States
Zip Code
85013
Householder, Kyle T; DiPerna, Danielle M; Chung, Eugene P et al. (2018) pH driven precipitation of quisinostat onto PLA-PEG nanoparticles enables treatment of intracranial glioblastoma. Colloids Surf B Biointerfaces 166:37-44
Truong, Danh; Fiorelli, Roberto; Barrientos, Eric S et al. (2018) A three-dimensional (3D) organotypic microfluidic model for glioma stem cells - Vascular interactions. Biomaterials :
Griveau, Amelie; Seano, Giorgio; Shelton, Samuel J et al. (2018) A Glial Signature and Wnt7 Signaling Regulate Glioma-Vascular Interactions and Tumor Microenvironment. Cancer Cell 33:874-889.e7
Mehta, Shwetal (2018) Editorial: The Role of Microenvironment in the Homing, Maintenance, and Release of Glioma Stem-Like Cells. Front Oncol 8:7
Mehta, Shwetal; Lo Cascio, Costanza (2018) Developmentally regulated signaling pathways in glioma invasion. Cell Mol Life Sci 75:385-402
Kosty, Jennifer; Lu, Fanghui; Kupp, Robert et al. (2017) Harnessing OLIG2 function in tumorigenicity and plasticity to target malignant gliomas. Cell Cycle 16:1654-1660
Heffernan, John M; McNamara, James B; Borwege, Sabine et al. (2017) PNIPAAm-co-Jeffamine® (PNJ) scaffolds as in vitro models for niche enrichment of glioblastoma stem-like cells. Biomaterials 143:149-158
Singh, Shiv K; Fiorelli, Roberto; Kupp, Robert et al. (2016) Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF-? Pathway. Cell Rep 16:950-966
Kupp, Robert; Shtayer, Lior; Tien, An-Chi et al. (2016) Lineage-Restricted OLIG2-RTK Signaling Governs the Molecular Subtype of Glioma Stem-like Cells. Cell Rep 16:2838-2845